ClinicalTrials.gg
Enrolling by invitationNCT05477862Updated Aug 10, 2026

Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease

An interventional study of Clinically Designed Improvisatory Music in Alzheimer Disease, sponsored by Northwestern University. Enrolling by invitation at 1 site in United States. Open to participants aged 55 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Northwestern University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
55 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alzheimer Disease by Northwestern University — 5 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Northwestern University.

Planned enrollment
12th of 15
30 · median 105
Started
2023
with 1 other
No phase
14 of 16
5 open now
Registered
9th of 16
by date

Among the 16 studies in Alzheimer Disease by Northwestern University, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 14 with no phase, and was the 9th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

5 of the 16 studies in Alzheimer Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Northwestern University, or all of them as a file.
02

Study summary

Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients. As a direct sound-based approach, CDIM does not rely on autobiographical memory and may have wider applicability and generalizability. We wish to examine if CDIM decreases anxiety in 15 cognitively healthy individuals and 15 Alzheimer Disease patients with anxiety (AD-A).

Read the detailed description

The goal of this study is to identify the neural mechanisms of induced calmness through live clinically designed improvisatory music (CDIM) in cognitively healthy individuals and persons with Alzheimer's dementia suffering from agitation. This study is novel as most music interventions for dementia use familiar music and the underlying neural mechanism of calmness induced by music is not well known. We plan to investigate changes in 3 major large-scale brain networks using functional magnetic resonance imaging (fMRI). The major questions we plan to answer are as follows: 1. How does improvisatory music change the connectivity within brain emotion related networks in neurotypical individuals? 2. Does improvisatory music induce a state of calmness in individuals with Alzheimer's dementia and how? Based on objective evidence provided by this study we can justify further usage of music for patients with Alzheimer's, in particular, in the form of improvisation.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Anxiety
  • Alzheimer
  • Dementia
  • Agitation
  • Irritability
  • Music Intervention
  • Music Medicine
  • Music Improvisation
04

Who can participate

Ages eligible
55 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Cognitively healthy individuals

    Cognitively healthy control participants evaluated through the Northwestern Mesulam Center. BAI > 8.

    Exclusion Criteria: hearing loss

  2. Individuals with mild to moderate Alzheimer's disease

This group will similarly be recruited through the Mesulam Center. All individuals recruited by the research Core at the center are well characterized tests standardized across all NIH funded Alzheimer Centers across the nation. Individuals with mild to moderate neurocognitive disorder due to AD will have an greater than >15 and Clinical Dementia Rating (CDR) between 0.5 and 2.. They will also have a history of neurocognitive-related agitation/anxiety, and a Beck Anxiety Index (BAI) or Rating for Anxiety in Dementia (RAID) greater than 8, suggestive of at least a mild level of anxiety.

Exclusion criteria: MMSE\<15, CDR>2, hearing loss

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Alzheimer Disease (AD)

    Behavioral: Clinically Designed Improvisatory Music

  • Experimental
    Cognitively Healthy (CH)

    Behavioral: Clinically Designed Improvisatory Music

Interventions

  • BehavioralClinically Designed Improvisatory Music

    Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.

06

What researchers measure

Primary outcomes

  1. Change in Neuropsychiatric Inventory (NPI) [NPI-1: pre-intervention; NPI-2: post-intervention]

    Change in NPI (NPI-2 minus NPI-1)

    Time frame: Through study completion (3 years)

  2. Change in Beck Anxiety Inventory [BAI-1: pre-intervention; BAI-2: post-intervention]

    Change in BAI (BAI-2 minus BAI-1)

    Time frame: Through study completion (3 years)

Secondary outcomes

  1. Change in Systolic Blood Pressure [SBP-1: pre-intervention; SBP-2: post-intervention]

    Change in SBP (SBP-2 minus SBP-1)

    Time frame: Through study completion (3 years)

  2. Change in Heart rate [HR-1: pre-intervention; HR-2: post-intervention]

    Change in HR (HR-2 minus HR-1)

    Time frame: Through study completion (3 years)

  3. Change Respiratory Rate [RR-1: pre-intervention; RR-2: post-intervention]

    Change in RR (RR-2 minus RR-1)

    Time frame: Through study completion (3 years)

  4. Change in Skin conductance [SC-1: pre-intervention; SC-2: post-intervention]

    Change in SC (SC-2 minus SC-1)

    Time frame: Through study completion (3 years)

  5. Change in Resting state functional connectivity MRI

    Functional Connectivity within three resting state networks: Change in Default Network (DN), Change in Salience Network (SN), and Change in Reward Network (RN).

    Time frame: Through study completion (3 years)

07

Study locations

1 site
  • Mesulam Center for Cognitive Neurology and Alzheimer's Disease
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Bonakdarpour B, McFadden A, Zlotkowski S, Huang D, Shaker M, Shibata B, Haben W, Brashear C, Sandoval A, Breitenbach C, Rodriguez C, Viamille J, Porter M, Galic K, Schaeve M, Thatcher D, Takarabe C. Neurology Telemusic Program at the Time of the COVID-19 Pandemic: Turning Hospital Time Into Aesthetic Time During Crisis. Front Neurol. 2021 Dec 13;12:749782. doi: 10.3389/fneur.2021.749782. eCollection 2021. PubMed 34966344 ↗
  • Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011 Sep;7(5):532-9. doi: 10.1016/j.jalz.2011.05.2410. PubMed 21889116 ↗
  • Baird A, Samson S. Music and dementia. Prog Brain Res. 2015;217:207-35. doi: 10.1016/bs.pbr.2014.11.028. Epub 2015 Jan 31. PubMed 25725917 ↗
  • Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002 Aug;15(4):445-50. doi: 10.1097/00019052-200208000-00007. PubMed 12151841 ↗
  • Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007 Feb 28;27(9):2349-56. doi: 10.1523/JNEUROSCI.5587-06.2007. PubMed 17329432 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 39 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2022
First posted
Jul 28, 2022
StartActual
Sep 1, 2023
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05477862
Responsible party
Borna Bonakdarpour (Associate Professor of Neurology, Northwestern University) — Principal investigator
First posted
Jul 28, 2022
Start date
Sep 1, 2023
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Aug 10, 2026

Study contacts

Borna Bonakdarpour, MD, FAAN
principal investigator · Northwestern Mesulam Center for Cognitive Neurology and Alzheimer Disease

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion